Title: Development and Validation of a Nomogram for Predicting Endoscopic Healing in
Crohn's Disease Patients Receiving Infliximab Treatment
Version: 5 Date: 20 May 2025
Reviewer's report:
Thanks for addressing some of the concerns.  Please find the following comments:
- All the continuous variables should be reported as median (IQR), such as ESR and CRP.
- Regarding IM use, although it was noted as a limitation, I believe it should be reported in
table one and if there is any significant difference between groups, it should be included in
multivariate analysis
- There are multiple recent data confirming the role of clearance in IFX TDM, clinical outcomes,
and inflammatory burden. Please include this data if you have. If you do not have access, please
describe it as a limitation.
Title: Development and Validation of a Nomogram for Predicting Endoscopic Healing in
Crohn's Disease Patients Receiving Infliximab Treatment
Version: 5 Date: 20 May 2025
Reviewer's report:
Thanks for addressing some of the concerns.  Please find the following comments:
- All the continuous variables should be reported as median (IQR), such as ESR and CRP.
- Regarding IM use, although it was noted as a limitation, I believe it should be reported in
table one and if there is any significant difference between groups, it should be included in
multivariate analysis
- There are multiple recent data confirming the role of clearance in IFX TDM, clinical outcomes,
and inflammatory burden. Please include this data if you have. If you do not have access, please
describe it as a limitation.
Please review this paper.
user
Title: Development and Validation of a Nomogram for Predicting Endoscopic Healing in
Crohn's Disease Patients Receiving Infliximab Treatment
Version: 5 Date: 20 May 2025
Reviewer's report:
Thanks for addressing some of the concerns.  Please find the following comments:
- All the continuous variables should be reported as median (IQR), such as ESR and CRP.
- Regarding IM use, although it was noted as a limitation, I believe it should be reported in
table one and if there is any significant difference between groups, it should be included in
multivariate analysis
- There are multiple recent data confirming the role of clearance in IFX TDM, clinical outcomes,
and inflammatory burden. Please include this data if you have. If you do not have access, please
describe it as a limitation.
assistant